Abivax: Wall Street Catches Up to the Data

Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional demand.

EUROS aggregates the world's financial press. The full article lives with the newsroom that reported it.